Building on its expanding IP foundation, Lurex Bio’s portfolio—including the NeoTag™, Atraxis™, and Atraxis-X™ platforms—aims to overcome one of oncology’s greatest challenges: tumors that evade immune detection. The company’s work centers on restoring immune visibility to diseased cells through programmable molecular interfaces that help the body’s defenses identify, engage, and eliminate malignant or pathogenic targets more effectively.
Read Full Article on Boston Herald